Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera

Presented by Natera

Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does.

In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.

Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSC

Professor of Medicine & Medical Microbiology and Immunology
Director, Alberta Transplant Applied Genomics Centre
University of Alberta
Edmonton, AB Canada

Kieran Halloran, MD, MSc

Transplant Pulmonologist
Associate Professor
University of Alberta
Edmonton, AB Canada

Patrick Gauthier, PhD

Senior Data Scientist
Alberta Transplant Applied Genomics Centre
Edmonton, AB Canada

 

This episode was created for ISHLT Voices and sponsored by Natera.

The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.